Stevens, Vanessa W.
Stenehjem, David D.
Patterson, Olga V.
Kamauu, Aaron W. C.
Yim, Yeun Mi
Morlock, Robert J.
DuVall, Scott L.
Funding for this research was provided by:
Genentech Inc
Article History
Received: 24 August 2017
Revised: 3 April 2018
Accepted: 25 April 2018
First Online: 8 May 2018
Compliance with ethical standards
:
: SLD and OVP have received research funding through the University of Utah or Western Institute for Biomedical Research from the following for-profit organizations: Amgen Inc., AbbVie Inc., Anolinx LLC, AstraZeneca Pharmaceuticals LP, F. Hoffmann-La Roche Ltd, Genentech Inc., Genomic Health, Inc., Gilead Sciences Inc., HITEKS Solutions Inc., LexisNexis Risk Solutions, Merck & Co., Inc., Mylan Specialty LP, Northrop Grumman Information Systems, Novartis International AG, PAREXEL International Corporation, and Shire PLC. YMM and RM are employees of Genentech. VWS has received research funding through the University of Utah from Anolinx LLC, Merck & Co., Inc., and Pfizer Inc. DDS has received research funding through the University of Utah from the following for-profit organizations: Genentech Inc., AstraZeneca Pharmaceuticals LP, Myriad Genetics, Bristol-Myers Squibb, AbbVie Inc., and Novartis International AG. He has served as a paid consultant to the following for-profit organizations: Bristol-Myers Squibb, Myriad Genetics, Salarius Pharmaceuticals, and BetaCat Pharmaceuticals. AK is an owner of Anolinx.
: Institutional review board and Department of Veterans Affairs (VA) study and data access approvals were obtained.